{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["40(8)"],"submitter":["Stockler MR"],"pubmed_abstract":["Purpose
We previously reported that enzalutamide improved overall survival when added to standard of care in metastatic, hormone-sensitive prostate cancer. Here, we report its effects on aspects of health-related quality of life (HRQL).Methods
HRQL was assessed with the European Organisation for Research and Treatment of Cancer core quality-of-life questionnaire and QLM-PR25 at weeks 0, 4, 12, and then every 12 weeks until progression. Scores from week 4 to 156 were analyzed with repeated measures modeling to calculate group means and differences. Deterioration-free survival was from random assignment until the earliest of death, clinical progression, discontinuation of study treatment, or a worsening of 10 points or more from baseline in fatigue, physical function, cogniti"],"journal":["Journal of clinical oncology : official journal of the American Society of Clinical Oncology"],"pagination":["837-846"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC8906451"],"repository":["biostudies-literature"],"pubmed_title":["Health-Related Quality of Life in Metastatic, Hormone-Sensitive Prostate Cancer: ENZAMET (ANZUP 1304), an International, Randomized Phase III Trial Led by ANZUP."],"pmcid":["PMC8906451"],"pubmed_authors":["Horvath LG","Chi KN","Sandhu S","McDermott R","Hague WE","Chowdhury S","Thomson A","Sweeney CJ","Marx GM","Tan TH","Martin AJ","Reaume MN","McJannett M","Begbie SD","Williams SG","Davis ID","Coskinas X","Winter DG","North SA","Dhillon HM","Yip S","Frydenberg M","ENZAMET Trial Investigators and the Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP)","Joshua AM","Tan A","Parulekar WR","Pook DW","Vera-Badillo F","Stockler MR","McCaffrey J","Zhang AY","Lawrence NJ","Zielinski RR","Parnis F"],"additional_accession":[]},"is_claimable":false,"name":"Health-Related Quality of Life in Metastatic, Hormone-Sensitive Prostate Cancer: ENZAMET (ANZUP 1304), an International, Randomized Phase III Trial Led by ANZUP.","description":"Purpose
We previously reported that enzalutamide improved overall survival when added to standard of care in metastatic, hormone-sensitive prostate cancer. Here, we report its effects on aspects of health-related quality of life (HRQL).Methods
HRQL was assessed with the European Organisation for Research and Treatment of Cancer core quality-of-life questionnaire and QLM-PR25 at weeks 0, 4, 12, and then every 12 weeks until progression. Scores from week 4 to 156 were analyzed with repeated measures modeling to calculate group means and differences. Deterioration-free survival was from random assignment until the earliest of death, clinical progression, discontinuation of study treatment, or a worsening of 10 points or more from baseline in fatigue, physical function, cogniti","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Mar","modification":"2025-04-04T11:27:08.477Z","creation":"2024-11-08T20:27:47.559Z"},"accession":"S-EPMC8906451","cross_references":{"pubmed":["34928708"],"doi":["10.1200/JCO.21.00941"]}}